Pemetrexed, marketed by Eli Lilly and Company under the trade name Alimta, is a chemotherapeutic medication used to treat pleural mesothelioma and non-small cell lung cancer. Pemetrexed was approved by the US Food and Drug Administration in February 2004 for the treatment of malignant pleural mesothelioma, and the business got another FDA approval in 2008 for the treatment of advanced and metastatic non-small cell lung cancer.
Alimta is a folate analog metabolic inhibitor that is used to treat a variety of disorders when combined with other medications.
As a single agent for the maintenance and treatment of patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer (NSCLC). In combination with cisplatin for the initial treatment of patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer (NSCLC).
The approval and release of a low-cost generic version of pemetrexed are expected to boost its popularity.
The approval and release of a low-cost generic version of pemetrexed are expected to boost its popularity.
Alimta is a patented drug of Eli Lilly and Company that is protected in the United States by a vitamin regimen patent (2021) and pediatric exclusivity (2022), in major European countries by a vitamin regimen patent (2021), and in Japan by patents covering the use of vitamins to treat cancer concurrently with vitamins (2021).
However, the compound patent for Alimta held by Eli Lilly and Company expired in the United States in January 2017, and in major European nations and Japan in December 2015.
Several other major manufacturers have received regulatory permission for generic versions of pemetrexed, and these products are scheduled to hit the market throughout the projected period. The introduction of a low-cost generic variant is likely to boost sales.
Because of the high prevalence of non-small cell lung cancer and the high treatment rate in the United States, North America is projected to maintain its dominance.
According to Eli Lilly and Company's annual report for 2017, Alimta (pemetrexed) accounted for over half of the company's sales. As a result of the high frequency of non-small cell lung cancer and the high cost of therapy, North America is likely to be the most favorable region for pemetrexed market expansion.
According to the American Cancer Society's data from 2017, lung cancer (including small cell and non-small cell) is the second most frequent type of cancer in the United States, accounting for roughly 13% of all new cancer cases.
Eli Lilly and Company, Stada Arzneimittel AG, Eagle Pharmaceuticals, Inc., and others are among the major participants in the worldwide pemetrexed market.
Several other major manufacturers have received regulatory permission for generic versions of pemetrexed, and these products are scheduled to hit the market throughout the projected period. The introduction of a low-cost generic variant is likely to boost sales.
Because of the high prevalence of non-small cell lung cancer and the high treatment rate in the United States, North America is projected to maintain its dominance.
According to Eli Lilly and Company's annual report for 2017, Alimta (pemetrexed) accounted for over half of the company's sales. As a result of the high frequency of non-small cell lung cancer and the high cost of therapy, North America is likely to be the most favorable region for pemetrexed market expansion.
According to the American Cancer Society's data from 2017, lung cancer (including small cell and non-small cell) is the second most frequent type of cancer in the United States, accounting for roughly 13% of all new cancer cases.
Eli Lilly and Company, Stada Arzneimittel AG, Eagle Pharmaceuticals, Inc., and others are among the major participants in the worldwide pemetrexed market.
0 Comments